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Abstract Six synthesized 6-nitroquipazine derivatives
were examined by electron ionization (EI) and electrospray
ionization (ESI) mass spectrometry in positive and negative
ion mode. The compounds exhibit high affinity for the
serotonin transporter (SERT) and belong to a new class of
SERT inhibitors. The EI mass spectra registered in negative
ion mode showed prominent molecular ions for all the
compounds studied. All EI mass spectra and all ESI mass
spectra showed similar fragmentation pathways of molec-
ular ions, but the pathways differed between EI and ESI.
The differences were explained with the aid of theoretical
evaluation of the stability of the respective radical ions (EI
MS) and protonated ions (ESI MS).
Keywords Alkylnitroquipazines.Serotonin transporter
inhibitors.Semiempirical geometry and charge distribution
optimization.Electron ionization mass spectrometry.
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Introduction
The serotonin (5-HT) transporter (SERT), together with
dopamine and noradrenaline transporters, belongs to the
neurotransmitter sodium symporter family [1]. SERTacts as
a cotransporter of sodium and chloride ions, and of 5-HT
molecules [2–4]. The human SERT consists of 630 amino
acids with putative 12 transmembrane domains and
cytoplasmic N- and C-terminal domains [5, 6]. SERT is
located in the membrane of presynaptic serotonergic
neurons and transports the neurotransmitter 5-HT back into
the presynaptic neuron after its release into the synaptic
cleft [7]. Hence, SERT plays an important role in
termination of 5-HT-mediated neuronal signalling.
The transporter is targeted by the tricyclic antidepressant
and selective 5-HT reuptake inhibitor (SSRI) classes of
antidepressantdrugsaswellasbypsychostimulantcompounds
such as amphetamines and cocaine. The compounds act by
inhibitingSERT,causingincreased levelsof5-HTavailable for
interaction with postsynaptic 5-HT receptors [8]. SSRIs are
today the most widely used agents for the treatment of
depression and many additional neuropsychiatric and related
disorders [9]. The SSRIs act by blocking 5-HT reuptake, thus
increasing the concentration of 5-HT at the synapse,
enhancing the serotonergic neuronal transmission. A variety
of SSRIs such as fluoxetine and paroxetine have been
Published in the 10th Anniversary Issue.
Electronic supplementary material The online version of this article
(doi:10.1007/s00216-011-5410-8) contains supplementary material,
which is available to authorized users.
J. Witowska-Jarosz: M. Jarończyk:A. P. Mazurek:
Z. Chilmonczyk
National Medicines Institute,
Chełmska 30/34,
00-725 Warsaw, Poland
I. Sylte
Medical Pharmacology and Toxicology, Department of Medical
Biology, Faculty of Health Sciences, University of Tromsø,
9037 Tromsø, Norway
A. J. Bojarski
Department of Medicinal Chemistry, Institute of Pharmacology,
Polish Academy of Sciences,
Smętna 12,
31-343 Cracow, Poland
M. Jarosz (*)
Chair of Analytical Chemistry, Faculty of Chemistry,
Warsaw University of Technology,
Noakowskiego 3,
00-664 Warsaw, Poland
e-mail: mj@ch.pw.edu.pl
Anal Bioanal Chem (2012) 402:537–541
DOI 10.1007/s00216-011-5410-8developed for the treatment of depression [7]. However, there
is still a need to identify other modulators of SERT given the
large number of neurological and psychiatric diseases
associated with transporter defects. The available SSRIs are
known to have side effects such as, but not limited to,
anxiety, impotency and sleep disorders. However, a major
problem with SSRIs is that they have a 2–4-week delayed
onset of action [10, 11]. Thus, new therapeutic agents are
needed that are safer and more effective than known SSRIs.
We synthesized new SERT inhibitors of general structure
A shown in Fig. 1a, exhibiting high affinity for the
transporter. The compounds were subjected to pharmaco-
a
b 
Fig. 1 Structures of compounds
1–6 (a) and their fragmentation
patterns observed by electron
ionization (EI) and electrospray
ionization (ESI) mass spectrom-
etry (MS) in positive ion mode
(b)
538 J. Witowska-Jarosz et al.logical tests in vitro and in vivo. Some of them exhibited
agonistic activity at presynaptic 5-HT1A receptors as well as
antidepressant activity in an animal model of depression
(Porsolt test). We have also determined basic parameters
that are useful for explanation of the biological activity
trends and conducted docking of the compounds to
homology-based SERT models [12]. In this work, we
examine electron ionization (EI) and electrospray ionization
(ESI) mass spectra in positive and negative ion mode of
compounds 1–6 in Fig. 1a, exhibiting high affinity for
SERT and belonging to a new class of SERT inhibitors.
Experimental
Mass spectrometry
EI mass spectra were recorded in positive and negative full-
scanmodewithuseofaFinniganMATSSQ7000single-stage
quadrupole mass spectrometer capable of EI, chemical
ionization, atmospheric pressure chemical ionization and ESI.
A PC running on the X-calibur operating system was used for
data acquisition and data processing. The parameters of the EI
source were as follows: emission current 1.3 mA, electron
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Fig. 2 Mass spectra of
4′-cyclopentylmethyl-
6-nitroquipazine (3, Mr=340,
C13H24N4O2): EI in positive
(top) and negative (middle) ion
mode, and ESI MS and ESI
MS/MS fragmentation of the
protonated molecular ion at
m/z 341 (bottom in frame)
MS studies of 6-nitroquipazines 539energy 70 eV, sample introduction with the aid of a direct-inlet
probe.
ESI mass spectra were recorded with the aid of a Bruker
Daltonics MicrOTOF-Q II mass spectrometer capable of
high-resolution mass spectrometry (MS) and MS/MS. The
parameters of the ESI source were as follows: capillary
voltage 4,500 V, end plate offset voltage −500 V, collision
energy 20–35 eV, nebulizer pressure 0.8 bar, drying
temperature 170°C, dry gas flow rate 8 L min
-1.
Samples (2 μL in methanol) were injected into the
ESI source directly and after separation by an Ultimate
3000 (DIONEX) high-performance liquid chromatogra-
phy system equipped with a 136/CF column and an
auxiliary UV detector (λ=256 nm); the flow rate was
0.15 mL min
-1. For high-performance liquid chromatog-
raphy, gradient elution of solvents A (900:100:1 v/v/v
water–acetonitrile–trifluoroacetic acid) and B (900:100:1
v/v/v methanol–acetonitrile–trifluoroacetic acid) was
employed: 0–2 min 10% solvent B, 7 min 90% solvent
B, 12–14 min 10% solvent B.
Theoretical calculations
The geometry optimization as well as calculation of the
charge distribution in the cation radical, and calculation
of the relative stability of protonated species of
compound 3 were performed using the semiempirical
A M 1m e t h o da si m p l e m e n t e di nt h eS p a r t a n ’04 program
[13].
Results and discussion
Hard (electron) and soft (electrospray) ionization techniques
were used for mass spectrometric studies of new alkylnitro-
quipazine derivatives exhibiting potential antidepressant
activity. The EI spectra of compounds 1–6 (Figs. 2,S 1)
showed the presence of ions containing substituents (R) with
fragments of a piperazine ring ([RNC3H5]
+ and [RNC4H6]
+
(Table 1,F i g .1b, fragments a and b, respectively). For
compounds 1–4, base peaks corresponded to [RNC3H5]
+
ions, whereas for compounds 5 and 6 (possessing an
aromatic R substituent), base peaks were attributed to benzyl
(m/z 91) and fluorobenzyl (m/z 109) fragment ions (Fig. 1b,
fragments f and g, respectively). The small intensity signals
at m/z 202 and 214 corresponded to the ions formed after
subtraction of [RNC3H5] and [RNC2H4] from molecular ion
moieties, respectively. 6-Nitroquipazine ion, [M-R]
+,w a s
registered at m/z 257. Typical fragmentation of nitro-group-
containing aromatic compounds [14] with formation of
[M-O]
+,[ M - N O ]
+ and [M-NO2]
+ ions was not observed.
In addition to the usually registered positive ions, negative
ions can also be formed during EI (Fig. S2). The efficiency of
this process is substantially lower and the lifetimes of the
negative ions are shorter (they are more unstable and seldom
examined). However, for 6-nitroquipazine derivatives 1–6,
strong signals of negative molecular anions M
•− (100%
relative abundance) occurred as a result of thermal electron
capture. They can serve as a source of information for the
molecular masses of the compounds examined, as the
intensity of the molecular ions registered in positive ion
mode, M
•+,i sl o w( 5 –20%) and diminishes with increased
length of the aliphatic substituent.
The ions appeared to be relatively stable, since no
fragment ions in considerable amounts were registered. The
stability of the ions was explained by the presence of a nitro
substituent at the aromatic quinoline ring.
The ESI technique in positive ion mode showed mainly
protonated molecular ions, [M + H]
+, for all compounds
investigated. MS/MS was appliedt os e a r c hf o rf r a g m e n t a t i o n
of these pseudomolecular ions. For all compounds, mainly
fragment ions at m/z 216 were registered, followed by ions at
m/z 170 (Figs.2,S 3). Exact mass measurements were performed
to confirm the elemental composition of each ion registered.
Table 1 Electron ionization mass spectrometry: positive fragment ions of 4′-R-substituted 6-nitroquipazines
Compound R Molecular ion
M
+ m/z (%)
a
Base peak m/zm /z (%)
a [RNC4H6
+]
c Other ions m/z
R
+ [RNC3H5
+]
b
1 n-Octyl 370 (10%) - 168 181 (31%) 43, 56, 70, 125, 156, 166, 202, 214, 216, 271
2 n-Dodecyl 426 (5%) - 224 237 (29%) 43, 56, 70, 125, 202, 212, 222 , 271
3 Cyclopentylmethyl 340 (12%) - 138 151 (70%) 41, 56, 70, 82, 126, 170, 202, 216, 271, 322
4 Cyclohexyl 340 (20%) - 138 151 (30%) 56, 83, 112, 126, 156, 196, 202, 214, 314
5 Benzyl 348 (17%) 91 146 (30%) 159 (30%) 56, 65, 202, 214, 257
6 Fluorobenzyl 366 (15%) 109 164 (40%) 177 (43%) 56, 83, 202, 214, 257
aIn parentheses, the relative intensity
bFragment a from Fig. 1b
cFragment b from Fig. 1b
540 J. Witowska-Jarosz et al.The ions at m/z 216.076 (C11H10N3O2) correspond to the
protonated fragments c or d (Fig. 1b) resulting from
breaking of the piperazine ring. The ions of low intensity
at m/z 170 originate from subtraction of the nitro group
from ions at m/z 216. Similar to the EI spectra, the ESI
spectra of compounds 5 and 6 showed ions at m/z 91 and
m/z 109 (Fig. 1b, fragments f and g), which correspond to
benzyl and fluorobenzyl substituents (C7H7
+ and C7H6F
+,
respectively). No negative ions of 6-nitroquipazines 1–6
were observed in the ESI mass spectra.
In both EI and ESI mass spectra, very intense peaks
corresponding to piperazinering fragmentationwere observed.
However, it should be noted that the very intense peaks in the
EI mass spectra correspond to the R substituent connected to
the piperazine 4′ nitrogen atom (Fig. 1b, fragments a and b).
Theoretical calculations of the charge distribution of the
electron-deficient molecular ion of compound 3 (formed
during EI) showed the highest positive charge on the N-4′
nitrogen atom. On the other hand, in the ESI mass spectra
peaks corresponding to charged nitroaminoquinoline (Fig. 1b,
fragments c and d) had high intensity. Calculations of
putative protonation sites formed during electrospray ioniza-
tion showed that highest theoretical stability was obtained
with the N-1 nitrogen atom protonated (relative energy
197.370241 kcal/mol), followed by protonation at the N-4′
(relative energy 200.034900 kcal/mol) and then protonation
at the N-1′ (relative energy 229.024006 kcal/mol) nitrogen
atoms. That would thus explain the formation of charged
fragments c and d (Fig. 1b).
In conclusion, EI and ESI mass spectra of new SERT
inhibitors have been reported, and it was found that in EI
the main fragment ions contained R substituents whereas in
ESI they contained a nitroquinoline moiety. The results
obtained show that the negative ions in EI may be quite
stable when a nitroaromatic moiety is present in the
molecule. Theoretical calculations of the stability of
electron-deficient and protonated daughter ions may help
in explaining the fragmentation pattern of molecular ions
and the relative ion stability.
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